French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease

Carioli, 2020, European cancer mortality predictions for the year 2020 with a focus on prostate cancer, Ann Oncol, 31, 650, 10.1016/j.annonc.2020.02.009

Grosclaude, 2015, [Prostate cancer incidence and mortality trends in France from 1980 to 2011], Prog Urol, 25, 536, 10.1016/j.purol.2015.04.011

Brureau, 2020, Endocrine disrupting-chemicals and biochemical recurrence of prostate cancer after prostatectomy: a cohort study in Guadeloupe (French West Indies), Int J Cancer, 146, 657, 10.1002/ijc.32287

Multigner, 2010, Chlordecone exposure and risk of prostate cancer, J Clin Oncol, 28, 3457, 10.1200/JCO.2009.27.2153

Blanc-Lapierre, 2015, Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, Canada, BMC Public Health, 15, 913, 10.1186/s12889-015-2260-x

Esposito, 2013, Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis, J Endocrinol Invest, 36, 132, 10.1007/BF03346748

Davies, 2015, The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium, Cancer Causes Control, 26, 1603, 10.1007/s10552-015-0654-9

Vidal, 2014, Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study, Cancer Epidemiol Biomarkers Prev, 23, 2936, 10.1158/1055-9965.EPI-14-0795

Lenfant, 2020, Testosterone replacement therapy (TRT) and prostate cancer: an updated systematic review with a focus on previous or active localized prostate cancer, Urol Oncol, 38, 661, 10.1016/j.urolonc.2020.04.008

Lippman, 2009, Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT), JAMA, 301, 39, 10.1001/jama.2008.864

Unger, 2018, Using medicare claims to examine long-term prostate cancer risk of finasteride in the prostate cancer prevention trial, J Natl Cancer Inst, 110, 1208

Andriole, 2010, Effect of dutasteride on the risk of prostate cancer, N Engl J Med, 362, 1192, 10.1056/NEJMoa0908127

Thompson, 2003, The influence of finasteride on the development of prostate cancer, N Engl J Med, 349, 215, 10.1056/NEJMoa030660

Preston, 2014, Metformin use and prostate cancer risk, Eur Urol, 66, 1012, 10.1016/j.eururo.2014.04.027

Freedland, 2013, Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study, Prostate Cancer Prostatic Dis, 16, 254, 10.1038/pcan.2013.10

Leongamornlert, 2014, Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease, Br J Cancer, 110, 1663, 10.1038/bjc.2014.30

Xu, 2013, HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG), Hum Genet, 132, 5, 10.1007/s00439-012-1229-4

Nyberg, 2019, Homeobox B13 G84E mutation and prostate cancer risk, Eur Urol, 75, 834, 10.1016/j.eururo.2018.11.015

Oh, 2019, The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: a meta-analysis, Prostate, 79, 880, 10.1002/pros.23795

Patel, 2020, Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness, Cancer Res, 80, 624, 10.1158/0008-5472.CAN-19-1840

Al Olama, 2014, A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer, Nat Genet, 46, 1103, 10.1038/ng.3094

Schumacher, 2018, Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci, Nat Genet, 50, 928, 10.1038/s41588-018-0142-8

Ploussard, 2022, [DNA repair gene alterations testing in prostate cancer: a practical update by the prostate cancer committee of the French Association of Urology], Prog Urol, 32, 155, 10.1016/j.purol.2021.12.007

Nicolosi, 2019, Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines, JAMA Oncol, 5, 523, 10.1001/jamaoncol.2018.6760

Pritchard, 2016, Inherited DNA-repair gene mutations in men with metastatic prostate cancer, N Engl J Med, 375, 443, 10.1056/NEJMoa1603144

Carter, 2019, Germline mutations in ATM and BRCA1/2 are associated with grade reclassification in men on active surveillance for prostate cancer, Eur Urol, 75, 743, 10.1016/j.eururo.2018.09.021

Page, 2019, Interim results from the IMPACT Study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers, Eur Urol, 76, 831, 10.1016/j.eururo.2019.08.019

Barnes, 2022, Breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers using polygenic risk scores, J Natl Cancer Inst, 114, 109, 10.1093/jnci/djab147

Segal, 2020, Imaging-based prostate cancer screening among BRCA mutation carriers – results from the first round of screening, Ann Oncol, 31, 1545, 10.1016/j.annonc.2020.06.025

Mohler, 2019, Prostate Cancer, Version 2.2019, NCCN Clinical practice guidelines in oncology, J Natl Compr Canc Netw, 17, 479, 10.6004/jnccn.2019.0023

Tonon, 2019, Mutational profile of aggressive, localised prostate cancer from African Caribbean men versus European ancestry men, Eur Urol, 75, 11, 10.1016/j.eururo.2018.08.026

de Bono, 2020, Olaparib for metastatic castration-resistant prostate cancer, N Engl J Med, 382, 2091, 10.1056/NEJMoa1911440

de Bono, 2021, Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial, Lancet Oncol, 22, 1250, 10.1016/S1470-2045(21)00376-4

Abida, 2019, Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade, JAMA Oncol, 5, 471, 10.1001/jamaoncol.2018.5801

Ilic, 2013, Screening for prostate cancer, Cochrane Database Syst Rev, CD004720

Hayes, 2014, Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence, JAMA, 311, 1143, 10.1001/jama.2014.2085

Schroder, 2014, Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up, Lancet, 384, 2027, 10.1016/S0140-6736(14)60525-0

Hugosson, 2019, A 16-yr follow-up of the european randomized study of screening for prostate cancer, Eur Urol, 76, 43, 10.1016/j.eururo.2019.02.009

Booth, 2014, Health-related quality of life in the Finnish trial of screening for prostate cancer, Eur Urol, 65, 39, 10.1016/j.eururo.2012.11.041

Vasarainen, 2013, Effects of prostate cancer screening on health-related quality of life: results of the Finnish arm of the European randomized screening trial (ERSPC), Acta Oncol, 52, 1615, 10.3109/0284186X.2013.802837

Heijnsdijk, 2012, Quality-of-life effects of prostate-specific antigen screening, N Engl J Med, 367, 595, 10.1056/NEJMoa1201637

Gandaglia, 2019, Structured population-based prostate-specific antigen screening for prostate cancer: the European Association of Urology position in 2019, Eur Urol, 76, 142, 10.1016/j.eururo.2019.04.033

Albright, 2015, Prostate cancer risk prediction based on complete prostate cancer family history, Prostate, 75, 390, 10.1002/pros.22925

Chornokur, 2011, Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer, Prostate, 71, 985, 10.1002/pros.21314

Clements, 2021, Defining the impact of family history on detection of high-grade prostate cancer in a large multi-institutional cohort, Eur Urol, 82, 163, 10.1016/j.eururo.2021.12.011

Wallstrom, 2022, Prostate cancer screening with magnetic resonance imaging: results from the second round of the Goteborg Prostate Cancer Screening 2 Trial, Eur Urol Oncol, 5, 54, 10.1016/j.euo.2021.09.001

Lilja, 2007, Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years, J Clin Oncol, 25, 431, 10.1200/JCO.2006.06.9351

Vickers, 2013, Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long-term risk of metastasis: case-control study, BMJ, 346, f2023, 10.1136/bmj.f2023

Preston, 2016, Baseline prostate-specific antigen levels in midlife predict lethal prostate cancer, J Clin Oncol, 34, 2705, 10.1200/JCO.2016.66.7527

Kovac, 2020, JAMA Netw Open, 3, e1919284, 10.1001/jamanetworkopen.2019.19284

Heijnsdijk, 2020, Lifetime benefits and harms of prostate-specific antigen-based risk-stratified screening for prostate cancer, J Natl Cancer Inst, 112, 1013, 10.1093/jnci/djaa001

Van Poppel, 2021, A European model for an organised risk-stratified early detection programme for prostate cancer, Eur Urol Oncol, 4, 731, 10.1016/j.euo.2021.06.006

Gosselaar, 2008, The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam, Eur Urol, 54, 581, 10.1016/j.eururo.2008.03.104

Thompson, 2004, Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter, N Engl J Med, 350, 2239, 10.1056/NEJMoa031918

Borkenhagen, 2019, Digital rectal examination remains a key prognostic tool for prostate cancer: a national cancer database review, J Natl Compr Canc Netw, 17, 829, 10.6004/jnccn.2018.7278

Bruun, 2005, Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden, Prostate, 65, 216, 10.1002/pros.20286

Nordstrom, 2018, Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer, Prostate Cancer Prostatic Dis, 21, 57, 10.1038/s41391-017-0024-7

Stavrinides, 2021, Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models, Prostate Cancer Prostatic Dis, 24, 1028, 10.1038/s41391-021-00373-w

Manceau, 2021, Biomarker in active surveillance for prostate cancer: a systematic review, Cancers (Basel), 13

Lamy, 2018, Prognostic biomarkers used for localised prostate cancer management: a systematic review, Eur Urol Focus, 4, 790, 10.1016/j.euf.2017.02.017

Cornelis, 2013, Real-time contrast-enhanced transrectal US-guided prostate biopsy: diagnostic accuracy in men with previously negative biopsy results and positive MR imaging findings, Radiology, 269, 159, 10.1148/radiol.13122393

Schiffmann, 2016, Limitations of elastography based prostate biopsy, J Urol, 195, 1731, 10.1016/j.juro.2015.12.086

Lughezzani, 2019, Comparison of the diagnostic accuracy of micro-ultrasound and magnetic resonance imaging/ultrasound fusion targeted biopsies for the diagnosis of clinically significant prostate cancer, Eur Urol Oncol, 2, 329, 10.1016/j.euo.2018.10.001

Ghai, 2016, Assessing cancer risk on novel 29 MHz micro-ultrasound images of the prostate: creation of the micro-ultrasound protocol for prostate risk identification, J Urol, 196, 562, 10.1016/j.juro.2015.12.093

Sountoulides, 2021, Micro-ultrasound-guided vs. multiparametric magnetic resonance imaging-targeted biopsy in the detection of prostate cancer: a systematic review and meta-analysis, J Urol, 205, 1254, 10.1097/JU.0000000000001639

Fasulo, 2022, Use of high-resolution micro-ultrasound to predict extraprostatic extension of prostate cancer prior to surgery: a prospective single-institutional study, World J Urol, 40, 435, 10.1007/s00345-021-03890-4

Turkbey, 2019, Prostate Imaging Reporting and Data System Version 2.1: 2019 update of prostate imaging reporting and data system version 2, Eur Urol, 76, 340, 10.1016/j.eururo.2019.02.033

Bjurlin, 2020, Update of the standard operating procedure on the use of multiparametric magnetic resonance imaging for the diagnosis, staging and management of prostate cancer, J Urol, 203, 706, 10.1097/JU.0000000000000617

van der Leest, 2019, High diagnostic performance of short magnetic resonance imaging protocols for prostate cancer detection in biopsy-naive men: the next step in magnetic resonance imaging accessibility, Eur Urol, 76, 574, 10.1016/j.eururo.2019.05.029

Schoots, 2021, PI-RADS Committee Position on MRI without contrast medium in biopsy-naive men with suspected prostate cancer: narrative review, AJR Am J Roentgenol, 216, 3, 10.2214/AJR.20.24268

Drost, 2020, Prostate magnetic resonance imaging, with or Without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: a Cochrane systematic review and meta-analysis, Eur Urol, 77, 78, 10.1016/j.eururo.2019.06.023

Tamada, 2008, Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis, Radiology, 248, 531, 10.1148/radiol.2482070157

Turkbey, 2011, Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images?, Radiology, 258, 488, 10.1148/radiol.10100667

Kasivisvanathan, 2018, MRI-targeted or standard biopsy for prostate-cancer diagnosis, N Engl J Med, 378, 1767, 10.1056/NEJMoa1801993

Klotz, 2021, Comparison of multiparametric magnetic resonance imaging-targeted biopsy with systematic transrectal ultrasonography biopsy for biopsy-naive men at risk for prostate cancer: a phase 3 randomized clinical trial, JAMA Oncol, 7, 534, 10.1001/jamaoncol.2020.7589

Rouviere, 2019, Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study, Lancet Oncol, 20, 100, 10.1016/S1470-2045(18)30569-2

van der Leest, 2019, Eur Urol, 75, 570, 10.1016/j.eururo.2018.11.023

Nordstrom, 2021, Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial, Lancet Oncol, 22, 1240, 10.1016/S1470-2045(21)00348-X

Eklund, 2021, MRI-targeted or standard biopsy in prostate cancer screening, N Engl J Med, 385, 908, 10.1056/NEJMoa2100852

Falagario, 2021, Combined use of prostate-specific antigen density and magnetic resonance imaging for prostate biopsy decision planning: a retrospective multi-institutional study using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD), Eur Urol Oncol, 4, 971, 10.1016/j.euo.2020.08.014

Li, 2019, Comparison of PET/MRI with multiparametric MRI in diagnosis of primary prostate cancer: a meta-analysis, Eur J Radiol, 113, 225, 10.1016/j.ejrad.2019.02.028

Eiber, 2016, Simultaneous (68)Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer, Eur Urol, 70, 829, 10.1016/j.eururo.2015.12.053

Jena, 2018, Improving diagnosis of primary prostate cancer with combined (68)Ga-prostate-specific membrane antigen-HBED-CC simultaneous PET and multiparametric MRI and clinical parameters, AJR Am J Roentgenol, 211, 1246, 10.2214/AJR.18.19585

Bruyere, 2021, [Short recommendations from the CIAFU: interest of the urine bacterial culture performed before endo-rectal prostate biopsy], Prog Urol, 31, 245, 10.1016/j.purol.2020.10.003

Godier, 2019, Arch Cardiovasc Dis, 112, 199, 10.1016/j.acvd.2018.10.004

Aron, 2000, Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study, BJU Int, 85, 682, 10.1046/j.1464-410x.2000.00576.x

Roberts, 2017, Prostate biopsy-related infection: a systematic review of risk factors, prevention strategies, and management approaches, Urology, 104, 11, 10.1016/j.urology.2016.12.011

Bruyere, 2015, Prosbiotate: a multicenter, prospective analysis of infectious complications after prostate biopsy, J Urol, 193, 145, 10.1016/j.juro.2014.07.086

Pradere, 2021, Nonantibiotic strategies for the prevention of infectious complications following prostate biopsy: a systematic review and meta-analysis, J Urol, 205, 653, 10.1097/JU.0000000000001399

Bass, 2017, Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach, Prostate Cancer Prostatic Dis, 20, 311, 10.1038/pcan.2017.13

Ramedani, 2021, Topical antiseptic at time of transrectal ultrasound prostate biopsy is associated with fewer severe clinical infections and improves antibiotic stewardship, Prostate Int, 9, 185, 10.1016/j.prnil.2021.05.003

Jazayeri, 2020, A systematic review and meta-analysis of methods used to reduce infectious complications following transrectal prostate biopsy, Urology, 144, 21, 10.1016/j.urology.2020.06.005

Rai, 2021, Magnetic resonance imaging/ultrasound fusion-guided transperineal versus magnetic resonance imaging/ultrasound fusion-guided transrectal prostate biopsy – a systematic review, Eur Urol Oncol, 4, 904, 10.1016/j.euo.2020.12.012

Bajeot, 2021, Managing discordant findings between multiparametric magnetic resonance imaging and transrectal magnetic resonance imaging-directed prostate biopsy – the key role of magnetic resonance imaging-directed transperineal biopsy, Eur Urol Oncol, 5, 296, 10.1016/j.euo.2021.06.001

Ploussard, 2020, Assessment of the minimal targeted biopsy core number per MRI lesion for improving prostate cancer grading prediction, J Clin Med, 9, 25, 10.3390/jcm9010225

Lu, 2019, Role of core number and location in targeted magnetic resonance imaging-ultrasound fusion prostate biopsy, Eur Urol, 76, 14, 10.1016/j.eururo.2019.04.008

Leyh-Bannurah, 2020, Minimum magnetic resonance imaging-ultrasound fusion targeted biopsy cores needed for prostate cancer detection: multivariable retrospective, lesion based analyses of patients treated with radical prostatectomy, J Urol, 203, 299, 10.1097/JU.0000000000000527

Wegelin, 2019, The FUTURE Trial: a multicenter randomised controlled trial on target biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies, Eur Urol, 75, 582, 10.1016/j.eururo.2018.11.040

Bass, 2021, Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis, Prostate Cancer Prostatic Dis, 25, 174, 10.1038/s41391-021-00449-7

Fiard, 2020, What to expect from a non-suspicious prostate MRI? A review, Prog Urol, 30, 986, 10.1016/j.purol.2020.09.012

Buisset, 2021, Negative prebiopsy magnetic resonance imaging and risk of significant prostate cancer: baseline and long-term follow-up results, J Urol, 205, 725, 10.1097/JU.0000000000001414

Pagniez, 2020, Predictive factors of missed clinically significant prostate cancers in men with negative magnetic resonance imaging: a systematic review and meta-analysis, J Urol, 204, 24, 10.1097/JU.0000000000000757

Vesval, 2021, Should we perform systematic biopsies in case of suspicious MRI for prostate cancer in 2020? A review of literature, Prog Urol, 31, 147, 10.1016/j.purol.2020.09.025

Morote, 2022, The current recommendation for the management of isolated high-grade prostatic intraepithelial neoplasia, BJU Int, 129, 627, 10.1111/bju.15568

Borghesi, 2017, Complications after systematic, random, and image-guided prostate biopsy, Eur Urol, 71, 353, 10.1016/j.eururo.2016.08.004

van Leenders, 2020, The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma, Am J Surg Pathol, 44, e87, 10.1097/PAS.0000000000001497

Epstein, 2021, The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer, Arch Pathol Lab Med, 145, 461, 10.5858/arpa.2020-0015-RA

Epstein, 2016, The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system, Am J Surg Pathol, 40, 244, 10.1097/PAS.0000000000000530

Epstein, 2016, A Contemporary prostate cancer grading system: a validated alternative to the Gleason score, Eur Urol, 69, 428, 10.1016/j.eururo.2015.06.046

Hennes, 2021, The modified International Society of Urological Pathology system improves concordance between biopsy and prostatectomy tumour grade, BJU Int, 128 Suppl. 3, 45, 10.1111/bju.15556

van Leenders, 2020, Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups, Eur Urol, 77, 191, 10.1016/j.eururo.2019.07.051

Karram, 2011, Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings, Am J Surg Pathol, 35, 1351, 10.1097/PAS.0b013e3182217b79

Montironi, 2018, Features and prognostic significance of intraductal carcinoma of the prostate, Eur Urol Oncol, 1, 21, 10.1016/j.euo.2018.03.013

Zhou, 2018, High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate, Mod Pathol, 31, S71, 10.1038/modpathol.2017.138

Samaratunga, 2011, International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 1: specimen handling, Mod Pathol, 24, 6, 10.1038/modpathol.2010.178

Berney, 2011, International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 4: seminal vesicles and lymph nodes, Mod Pathol, 24, 39, 10.1038/modpathol.2010.160

Evans, 2011, Treatment effects in the prostate including those associated with traditional and emerging therapies, Adv Anat Pathol, 18, 281, 10.1097/PAP.0b013e318220f5b1

Lucia, 2007, Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial, J Natl Cancer Inst, 99, 1375, 10.1093/jnci/djm117

Bostwick, 2007, Diagnosis of prostatic carcinoma after therapy, Arch Pathol Lab Med, 131, 360, 10.5858/2007-131-360-DOPCAT

Mahal, 2018, Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer, Eur Urol, 74, 146, 10.1016/j.eururo.2018.01.043

Zelic, 2020, Predicting prostate cancer death with different pretreatment risk stratification tools: a head-to-head comparison in a nationwide cohort study, Eur Urol, 77, 180, 10.1016/j.eururo.2019.09.027

Dess, 2020, Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer, JAMA Oncol, 6, 735, 10.1001/jamaoncol.2020.0109

de Rooij, 2016, Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis, Eur Urol, 70, 233, 10.1016/j.eururo.2015.07.029

Jager, 1996, Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology, AJR Am J Roentgenol, 166, 845, 10.2214/ajr.166.4.8610561

Futterer, 2005, Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers, Radiology, 237, 541, 10.1148/radiol.2372041724

Bloch, 2012, Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI, Eur Radiol, 22, 2201, 10.1007/s00330-012-2475-5

Wang, 2004, Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension, Radiology, 232, 133, 10.1148/radiol.2321031086

Eifler, 2013, An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011, BJU Int, 111, 22, 10.1111/j.1464-410X.2012.11324.x

Briganti, 2012, Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores, Eur Urol, 61, 480, 10.1016/j.eururo.2011.10.044

Gandaglia, 2019, A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies, Eur Urol, 75, 506, 10.1016/j.eururo.2018.10.012

Hovels, 2008, The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis, Clin Radiol, 63, 387, 10.1016/j.crad.2007.05.022

Bhosale, 2013, What is the clinical significance of FDG unexpected uptake in the prostate in patients undergoing PET/CT for other malignancies?, Int J Mol Imaging, 2013, 476786, 10.1155/2013/476786

Schiavina, 2008, et al., 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms, Eur Urol, 54, 392, 10.1016/j.eururo.2008.04.030

Kjolhede, 2014, (1)(8)F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer, World J Urol, 32, 965, 10.1007/s00345-013-1189-x

Evangelista, 2013, Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis, Eur Urol, 63, 1040, 10.1016/j.eururo.2012.09.039

Simsek, 2021, Detection of metastases in newly diagnosed prostate cancer by using 68Ga-PSMA PET/CT and its relationship with modified D’Amico risk classification, Eur J Nucl Med Mol Imaging, 48, 1639, 10.1007/s00259-020-04995-5

Klingenberg, 2021, (68)Ga-PSMA PET/CT for primary lymph node and distant metastasis NM staging of high-risk prostate cancer, J Nucl Med, 62, 214, 10.2967/jnumed.120.245605

Hofman, 2020, Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study, Lancet, 395, 1208, 10.1016/S0140-6736(20)30314-7

Evangelista, 2021, PET/MRI in prostate cancer: a systematic review and meta-analysis, Eur J Nucl Med Mol Imaging, 48, 859, 10.1007/s00259-020-05025-0

Ling, 2021, Eur Urol Open Sci, 33, 61, 10.1016/j.euros.2021.09.006

Abdollah, 2015, More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer, Eur Urol, 67, 212, 10.1016/j.eururo.2014.05.011

Winter, 2014, Sentinel lymph node dissection in more than 1200 prostate cancer cases: rate and prediction of lymph node involvement depending on preoperative tumor characteristics, Int J Urol, 21, 58, 10.1111/iju.12184

Joniau, 2013, Mapping of pelvic lymph node metastases in prostate cancer, Eur Urol, 63, 450, 10.1016/j.eururo.2012.06.057

Abuzallouf, 2004, Baseline staging of newly diagnosed prostate cancer: a summary of the literature, J Urol, 171, 2122, 10.1097/01.ju.0000123981.03084.06

Palmedo, 2014, Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients, Eur J Nucl Med Mol Imaging, 41, 59, 10.1007/s00259-013-2532-6

Lecouvet, 2010, Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa), Eur Radiol, 20, 2973, 10.1007/s00330-010-1879-3

Gutzeit, 2010, Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma, Skeletal Radiol, 39, 333, 10.1007/s00256-009-0789-4

Shen, 2014, Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis, Skeletal Radiol, 43, 1503, 10.1007/s00256-014-1903-9

Poulsen, 2014, Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT, BJU Int, 114, 818, 10.1111/bju.12599

Anttinen, 2021, Eur Urol Oncol, 4, 635, 10.1016/j.euo.2020.06.012

Hillner, 2015, 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry, J Nucl Med, 56, 222, 10.2967/jnumed.114.150391

Langsteger, 2011, Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading, Q J Nucl Med Mol Imaging, 55, 448

Albertsen, 2011, Impact of comorbidity on survival among men with localized prostate cancer, J Clin Oncol, 29, 1335, 10.1200/JCO.2010.31.2330

Bill-Axelson, 2018, Radical prostatectomy or watchful waiting in prostate cancer – 29-year follow-up, N Engl J Med, 379, 2319, 10.1056/NEJMoa1807801

Wilt, 2020, Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the prostate cancer intervention versus observation trial (PIVOT), Eur Urol, 77, 713, 10.1016/j.eururo.2020.02.009

Donovan, 2016, Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer, N Engl J Med, 375, 1425, 10.1056/NEJMoa1606221

Hamdy, 2016, 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer, N Engl J Med, 375, 1415, 10.1056/NEJMoa1606220

Neal, 2020, Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received, Eur Urol, 77, 320, 10.1016/j.eururo.2019.10.030

Luzzago, 2020, A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings, BJU Int, 126, 104, 10.1111/bju.15048

Ploussard, 2020, Impact of MRI and targeted biopsies on eligibility and disease reclassification in MRI-positive candidates for active surveillance on systematic biopsies, Urology, 137, 126, 10.1016/j.urology.2019.10.039

Rajwa, 2021, Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during active surveillance: a systematic review and meta-analysis, Eur Urol, 80, 549, 10.1016/j.eururo.2021.05.001

Giganti, 2021, Update on multiparametric prostate MRI during active surveillance: current and future trends and role of the PRECISE recommendations, AJR Am J Roentgenol, 216, 943, 10.2214/AJR.20.23985

Moore, 2017, Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations – a report of a European School of Oncology Task Force, Eur Urol, 71, 648, 10.1016/j.eururo.2016.06.011

Klotz, 2020, Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up, Eur Urol, 77, 311, 10.1016/j.eururo.2019.10.007

Bratt, 2019, The value of an extensive transrectal repeat biopsy with anterior sampling in men on active surveillance for low-risk prostate cancer: a comparison from the randomised study of active monitoring in Sweden (SAMS), Eur Urol, 76, 461, 10.1016/j.eururo.2019.02.035

Lam, 2019, EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an International Collaborative Study (DETECTIVE Study), Eur Urol, 76, 790, 10.1016/j.eururo.2019.09.020

Tosoian, 2011, Active surveillance program for prostate cancer: an update of the Johns Hopkins experience, J Clin Oncol, 29, 2185, 10.1200/JCO.2010.32.8112

Tosoian, 2020, Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort, Eur Urol, 77, 675, 10.1016/j.eururo.2019.12.017

Forde, 2014, A single centre experience of active surveillance as management strategy for low-risk prostate cancer in Ireland, Ir J Med Sci, 183, 377, 10.1007/s11845-013-1024-9

Selvadurai, 2013, Medium-term outcomes of active surveillance for localised prostate cancer, Eur Urol, 64, 981, 10.1016/j.eururo.2013.02.020

Morash, 2015, Active surveillance for the management of localized prostate cancer: guideline recommendations, Can Urol Assoc J, 9, 171, 10.5489/cuaj.2806

Jain, 2015, Gleason upgrading with time in a large prostate cancer active surveillance cohort, J Urol, 194, 79, 10.1016/j.juro.2015.01.102

Klotz, 2015, Long-term follow-up of a large active surveillance cohort of patients with prostate cancer, J Clin Oncol, 33, 272, 10.1200/JCO.2014.55.1192

Bul, 2013, Active surveillance for low-risk prostate cancer worldwide: the PRIAS study, Eur Urol, 63, 597, 10.1016/j.eururo.2012.11.005

Preston, 2015, Active surveillance for low-risk prostate cancer: need for intervention and survival at 10 years, Urol Oncol, 33, 10.1016/j.urolonc.2015.04.015

Eggener, 2013, A multi-institutional evaluation of active surveillance for low risk prostate cancer, J Urol, 189, S19

Godtman, 2013, Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Goteborg randomised population-based prostate cancer screening trial, Eur Urol, 63, 101, 10.1016/j.eururo.2012.08.066

Loeb, 2015, Five-year nationwide follow-up study of active surveillance for prostate cancer, Eur Urol, 67, 233, 10.1016/j.eururo.2014.06.010

Filippou, 2015, Immediate versus delayed radical prostatectomy: updated outcomes following active surveillance of prostate cancer, Eur Urol, 68, 458, 10.1016/j.eururo.2015.06.011

van den Bergh, 2010, Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?, Cancer, 116, 1281, 10.1002/cncr.24882

Ornish, 2013, Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study, Lancet Oncol, 14, 1112, 10.1016/S1470-2045(13)70366-8

Parsons, 2014, A randomized trial of diet in men with early stage prostate cancer on active surveillance: rationale and design of the Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]), Contemp Clin Trials, 38, 198, 10.1016/j.cct.2014.05.002

Fleshner, 2012, Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial, Lancet, 379, 1103, 10.1016/S0140-6736(11)61619-X

Bill-Axelson, 2014, Radical prostatectomy or watchful waiting in early prostate cancer, N Engl J Med, 370, 932, 10.1056/NEJMoa1311593

Droz, 2010, Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults, Crit Rev Oncol Hematol, 73, 68, 10.1016/j.critrevonc.2009.09.005

Bill-Axelson, 2013, Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial, Eur Urol, 64, 920, 10.1016/j.eururo.2013.02.025

Yaxley, 2016, Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study, Lancet, 388, 1057, 10.1016/S0140-6736(16)30592-X

Ploussard, 2022, Annual nationwide analysis of costs and post-operative outcomes after radical prostatectomy according to the surgical approach (open, laparoscopic, and robotic), World J Urol, 40, 419, 10.1007/s00345-021-03878-0

Coughlin, 2018, Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study, Lancet Oncol, 19, 1051, 10.1016/S1470-2045(18)30357-7

Ilic, 2018, Laparoscopic and robot-assisted vs. open radical prostatectomy for the treatment of localized prostate cancer: a Cochrane systematic review, BJU Int, 121, 845, 10.1111/bju.14062

Ploussard, 2020, One-day prehabilitation program before robotic radical prostatectomy in daily practice: routine feasibility and benefits for patients and hospitals, Eur Urol Open Sci, 21, 14, 10.1016/j.euros.2020.06.009

Ploussard, 2020, A combination of enhanced recovery after surgery and prehabilitation pathways improves perioperative outcomes and costs for robotic radical prostatectomy, Cancer, 126, 4148, 10.1002/cncr.33061

Chang, 2016, Preoperative pelvic floor muscle exercise and postprostatectomy incontinence: a systematic review and meta-analysis, Eur Urol, 69, 460, 10.1016/j.eururo.2015.11.004

Martini, 2022, An algorithm to personalize nerve sparing in men with unilateral high-risk prostate cancer, J Urol, 207, 350, 10.1097/JU.0000000000002205

Tewari, 2011, Anatomical grades of nerve sparing: a risk-stratified approach to neural-hammock sparing during robot-assisted radical prostatectomy (RARP), BJU Int, 108, 984, 10.1111/j.1464-410X.2011.10565.x

Rosenberg, 2020, Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer, Cochrane Database Syst Rev, 8, CD013641

Rabbani, 2010, Comprehensive standardized report of complications of retropubic and laparoscopic radical prostatectomy, Eur Urol, 57, 371, 10.1016/j.eururo.2009.11.034

Ficarra, 2009, Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies, Eur Urol, 55, 1037, 10.1016/j.eururo.2009.01.036

Resnick, 2013, Functional outcomes after treatment for prostate cancer, N Engl J Med, 368, 1654

Alibhai, 2005, et al., 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity, J Natl Cancer Inst, 97, 1525, 10.1093/jnci/dji313

Haglind, 2015, Urinary incontinence and erectile dysfunction after robotic versus open radical prostatectomy: a prospective, controlled, nonrandomised trial, Eur Urol, 68, 216, 10.1016/j.eururo.2015.02.029

Heidenreich, 2007, Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy, Eur Urol, 52, 29, 10.1016/j.eururo.2007.04.020

Touijer, 2007, Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%, J Urol, 178, 120, 10.1016/j.juro.2007.03.018

Briganti, 2006, Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer, Eur Urol, 50, 1006, 10.1016/j.eururo.2006.08.015

Fossati, 2017, The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review, Eur Urol, 72, 84, 10.1016/j.eururo.2016.12.003

Touijer, 2021, Limited versus extended pelvic lymph node dissection for prostate cancer: a randomized clinical trial, Eur Urol Oncol, 4, 532, 10.1016/j.euo.2021.03.006

Lestingi, 2021, Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer: early oncological outcomes from a randomized phase 3 trial, Eur Urol, 79, 595, 10.1016/j.eururo.2020.11.040

Goy, 2020, Ten-year treatment outcomes of radical prostatectomy vs. external beam radiation therapy vs. brachytherapy for 1503 patients with intermediate-risk prostate cancer, Urology, 136, 180, 10.1016/j.urology.2019.09.040

Tom, 2020, Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy, Brachytherapy, 19, 43, 10.1016/j.brachy.2019.10.005

Merrick, 2017, Does supplemental external beam radiation therapy impact urinary, bowel, and erectile function following permanent prostate brachytherapy?: Results of two prospective randomized trials, J Contemp Brachytherapy, 9, 403, 10.5114/jcb.2017.70763

Frank, 2018, Prospective phase 2 trial of permanent seed implantation prostate brachytherapy for intermediate-risk localized prostate cancer: efficacy, toxicity, and quality of life outcomes, Int J Radiat Oncol Biol Phys, 100, 374, 10.1016/j.ijrobp.2017.09.050

Hoffman, 2020, Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer, JAMA, 323, 149, 10.1001/jama.2019.20675

Mendez, 2018, Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy, Brachytherapy, 17, 291, 10.1016/j.brachy.2017.10.001

Ennis, 2018, Brachytherapy-based radiotherapy and radical prostatectomy are associated with similar survival in high-risk localized prostate cancer, J Clin Oncol, 36, 1192, 10.1200/JCO.2017.75.9134

Kishan, 2018, Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9-10 prostate cancer, JAMA, 319, 896, 10.1001/jama.2018.0587

Kee, 2018, Brachytherapy versus external beam radiotherapy boost for prostate cancer: systematic review with meta-analysis of randomized trials, Cancer Treat Rev, 70, 265, 10.1016/j.ctrv.2018.10.004

Morris, 2017, Int J Radiat Oncol Biol Phys, 98, 275, 10.1016/j.ijrobp.2016.11.026

Rodda, 2017, ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer, Int J Radiat Oncol Biol Phys, 98, 286, 10.1016/j.ijrobp.2017.01.008

Rodda, 2017, ASCENDE-RT: an analysis of health-related quality of life for a randomized trial comparing low-dose-rate brachytherapy boost with dose-escalated external beam boost for high- and intermediate-risk prostate cancer, Int J Radiat Oncol Biol Phys, 98, 581, 10.1016/j.ijrobp.2017.02.027

King, 2019, A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer, Brachytherapy, 18, 186, 10.1016/j.brachy.2018.12.007

Bolla, 2016, Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC Trial 22991, J Clin Oncol, 34, 1748, 10.1200/JCO.2015.64.8055

Zapatero, 2015, High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial, Lancet Oncol, 16, 320, 10.1016/S1470-2045(15)70045-8

Pollack, 2013, Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer, J Clin Oncol, 31, 3860, 10.1200/JCO.2013.51.1972

Incrocci, 2016, Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial, Lancet Oncol, 17, 1061, 10.1016/S1470-2045(16)30070-5

Catton, 2017, Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer, J Clin Oncol, 35, 1884, 10.1200/JCO.2016.71.7397

Dearnaley, 2016, Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial, Lancet Oncol, 17, 1047, 10.1016/S1470-2045(16)30102-4

Lee, 2016, Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer, J Clin Oncol, 34, 2325, 10.1200/JCO.2016.67.0448

Langrand-Escure, 2018, Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: the French genito-urinary group (GETUG) recommendations, Cancer Radiother, 22, 193, 10.1016/j.canrad.2017.11.004

Widmark, 2019, Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial, Lancet, 394, 385, 10.1016/S0140-6736(19)31131-6

Jackson, 2019, Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6000 patients treated on prospective studies, Int J Radiat Oncol Biol Phys, 104, 778, 10.1016/j.ijrobp.2019.03.051

Lapierre, 2022, Highly hypofractionated schedules for localized prostate cancer: recommendations of the GETUG radiation oncology group, Crit Rev Oncol Hematol, 173, 103661, 10.1016/j.critrevonc.2022.103661

Murthy, 2021, Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial, J Clin Oncol, 39, 1234, 10.1200/JCO.20.03282

Crouzet, 2014, Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients, Eur Urol, 65, 907, 10.1016/j.eururo.2013.04.039

Ganzer, 2013, Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer, BJU Int, 112, 322, 10.1111/j.1464-410X.2012.11715.x

Thuroff, 2013, Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years, J Urol, 190, 702, 10.1016/j.juro.2013.02.010

Boutier, 2011, Location of residual cancer after transrectal high-intensity focused ultrasound ablation for clinically localized prostate cancer, BJU Int, 108, 1776, 10.1111/j.1464-410X.2011.10251.x

Ramsay, 2015, Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation, Health Technol Assess, 19, 1, 10.3310/hta19490

Dosanjh, 2021, High-intensity focused ultrasound for the treatment of prostate cancer: a national cohort study focusing on the development of stricture and fistulae, Eur Urol Focus, 7, 340, 10.1016/j.euf.2019.11.014

Mohammed, 2014, Cryotherapy and its applications in the management of urologic malignancies: a review of its use in prostate and renal cancers, Urol Oncol, 32, 10.1016/j.urolonc.2013.04.004

Elshafei, 2015, A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate, Prostate, 75, 1447, 10.1002/pros.23030

Levy, 2009, Primary cryoablation nadir prostate specific antigen and biochemical failure, J Urol, 182, 931, 10.1016/j.juro.2009.05.041

Fiard, 2021, Detailing sexual outcomes after focal therapy for localised prostate cancer: a systematic review and meta-analysis, Eur Urol Focus

Kleinclauss, 2019, [Vascular targeted photodynamic therapy in low-risk prostate cancer. A literature review], Prog Urol, 29, 393, 10.1016/j.purol.2019.05.004

van Luijtelaar, 2019, Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project, World J Urol, 37, 2147, 10.1007/s00345-019-02636-7

Bozzini, 2013, Focal therapy of prostate cancer: energies and procedures, Urol Oncol, 31, 155, 10.1016/j.urolonc.2012.05.011

Blazevski, 2020, Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment, BJU Int, 125, 369, 10.1111/bju.14951

Haffner, 2013, Tracking the clonal origin of lethal prostate cancer, J Clin Invest, 123, 4918, 10.1172/JCI70354

Valerio, 2015, Detection of clinically significant prostate cancer using magnetic resonance imaging-ultrasound fusion targeted biopsy: a systematic review, Eur Urol, 68, 8, 10.1016/j.eururo.2014.10.026

van der Poel, 2018, Focal therapy in primary localised prostate cancer: the European Association of Urology Position in 2018, Eur Urol, 74, 84, 10.1016/j.eururo.2018.01.001

Tay, 2017, Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project, Prostate Cancer Prostatic Dis, 20, 294, 10.1038/pcan.2017.8

Donaldson, 2015, Focal therapy: patients, interventions, and outcomes – a report from a consensus meeting, Eur Urol, 67, 771, 10.1016/j.eururo.2014.09.018

van den Bos, 2014, Focal therapy in prostate cancer: international multidisciplinary consensus on trial design, Eur Urol, 65, 1078, 10.1016/j.eururo.2014.01.001

Feijoo, 2016, Focal high-intensity focused ultrasound targeted hemiablation for unilateral prostate cancer: a prospective evaluation of oncologic and functional outcomes, Eur Urol, 69, 214, 10.1016/j.eururo.2015.06.018

Hopstaken, 2022, An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years?, Eur Urol, 81, 5, 10.1016/j.eururo.2021.08.005

Rischmann, 2017, Focal high intensity focused ultrasound of unilateral localized prostate cancer: a prospective multicentric hemiablation study of 111 patients, Eur Urol, 71, 267, 10.1016/j.eururo.2016.09.039

Lovegrove, 2020, Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry, BJU Int, 125, 853, 10.1111/bju.15004

Guillaumier, 2018, A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer, Eur Urol, 74, 422, 10.1016/j.eururo.2018.06.006

Ward, 2012, Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry, BJU Int, 109, 1648, 10.1111/j.1464-410X.2011.10578.x

Azzouzi, 2017, Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial, Lancet Oncol, 18, 181, 10.1016/S1470-2045(16)30661-1

De Groote, 2020, Techniques and outcomes of salvage robot-assisted radical prostatectomy (sRARP), Eur Urol, 78, 885, 10.1016/j.eururo.2020.05.003

Nathan, 2022, Comparative effectiveness analyses of salvage prostatectomy and salvage radiotherapy outcomes following focal or whole-gland ablative therapy (high-intensity focused ultrasound, cryotherapy or electroporation) for localised prostate cancer, Clin Oncol (R Coll Radiol), 34, e69, 10.1016/j.clon.2021.10.012

Hamdy, 2016, 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer, N Engl J Med, 375, 1415, 10.1056/NEJMoa1606220

Zumsteg, 2013, A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy, Eur Urol, 64, 895, 10.1016/j.eururo.2013.03.033

Keane, 2014, The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease, Cancer, 120, 1787, 10.1002/cncr.28609

Dall’Era, 2017, Active surveillance for intermediate-risk prostate cancer, Prostate Cancer Prostatic Dis, 20, 1, 10.1038/pcan.2016.51

Musunuru, 2016, Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook Experience, J Urol, 196, 1651, 10.1016/j.juro.2016.06.102

Partin, 1994, Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases, Urology, 43, 649, 10.1016/0090-4295(94)90180-5

Kishan, 2019, Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer, JAMA Netw Open, 2, e188006, 10.1001/jamanetworkopen.2018.8006

D’Amico, 2015, Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer, JAMA, 314, 1291, 10.1001/jama.2015.8577

Jones, 2011, Radiotherapy and short-term androgen deprivation for localized prostate cancer, N Engl J Med, 365, 107, 10.1056/NEJMoa1012348

Bolla, 2021, Short androgen suppression and radiation dose escalation in prostate cancer: 12-year results of EORTC Trial 22991 in patients with localized intermediate-risk disease, J Clin Oncol, 39, 3022, 10.1200/JCO.21.00855

Kishan, 2022, High-dose radiotherapy or androgen deprivation therapy (HEAT) as treatment intensification for localized prostate cancer: an individual patient-data network meta-analysis from the MARCAP Consortium, Eur Urol, 82, 106, 10.1016/j.eururo.2022.04.003

Kishan, 2022, Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis, Lancet Oncol, 23, 304, 10.1016/S1470-2045(21)00705-1

Kishan, 2022, Interplay between duration of androgen deprivation therapy and external beam radiotherapy with or without a brachytherapy boost for optimal treatment of high-risk prostate cancer: a patient-level data analysis of 3 cohorts, JAMA Oncol, 8, e216871, 10.1001/jamaoncol.2021.6871

Michalski, 2018, Effect of standard vs. dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG Oncology RTOG 0126 randomized clinical trial, JAMA Oncol, 4, e180039, 10.1001/jamaoncol.2018.0039

Nabid, 2021, Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial, Eur J Cancer, 143, 64, 10.1016/j.ejca.2020.10.023

Nabid, 2021, Optimizing treatment in intermediate-risk prostate cancer: secondary analysis of a randomized phase 3 trial, Int J Radiat Oncol Biol Phys, 111, 732, 10.1016/j.ijrobp.2021.04.013

Cosset, 2008, Selecting patients for exclusive permanent implant prostate brachytherapy: the experience of the Paris Institut Curie/Cochin Hospital/Necker Hospital group on 809 patients, Int J Radiat Oncol Biol Phys, 71, 1042, 10.1016/j.ijrobp.2007.11.056

Joniau, 2015, Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study, Eur Urol, 67, 157, 10.1016/j.eururo.2014.01.020

Stenmark, 2011, Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease, Int J Radiat Oncol Biol Phys, 81, e335, 10.1016/j.ijrobp.2011.04.037

Bolla, 2010, External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study, Lancet Oncol, 11, 1066, 10.1016/S1470-2045(10)70223-0

Souhami, 2010, Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31, Int J Radiat Oncol Biol Phys, 78, 1301, 10.1016/j.ijrobp.2009.10.007

Mason, 2015, Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer, J Clin Oncol, 33, 2143, 10.1200/JCO.2014.57.7510

Fossa, 2016, Eur Urol, 70, 684, 10.1016/j.eururo.2016.03.021

Denham, 2019, Lancet Oncol, 20, 267, 10.1016/S1470-2045(18)30757-5

Nabid, 2018, Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial, Eur Urol, 74, 432, 10.1016/j.eururo.2018.06.018

Roach, 2016, Prostate cancer: combining endocrine treatment and radiotherapy: a bright future, Nat Rev Urol, 13, 373, 10.1038/nrurol.2016.100

Spratt, 2021, Prostate radiotherapy with adjuvant androgen deprivation therapy (ADT) improves metastasis-free survival compared to neoadjuvant ADT: an individual patient meta-analysis, J Clin Oncol, 39, 136, 10.1200/JCO.20.02438

Boorjian, 2011, Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer, Cancer, 117, 2883, 10.1002/cncr.25900

Sooriakumaran, 2014, Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes, BMJ, 348, g1502, 10.1136/bmj.g1502

Petrelli, 2014, Radical prostatectomy or radiotherapy in high-risk prostate cancer: a systematic review and metaanalysis, Clin Genitourin Cancer, 12, 215, 10.1016/j.clgc.2014.01.010

Aluwini, 2016, Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial, Lancet Oncol, 17, 464, 10.1016/S1470-2045(15)00567-7

Fizazi, 2015, Androgen deprivation therapy plus docétaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial, Lancet Oncol, 16, 787, 10.1016/S1470-2045(15)00011-X

James, 2016, Addition of docétaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 387, 1163, 10.1016/S0140-6736(15)01037-5

Rosenthal, 2019, Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG Oncology RTOG 0521 Trial, J Clin Oncol, 37, 1159, 10.1200/JCO.18.02158

Eastham, 2020, Cancer and Leukemia Group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer, J Clin Oncol, 38, 3042, 10.1200/JCO.20.00315

Rajwa, 2022, Intensification of systemic therapy in addition to definitive local treatment in nonmetastatic unfavourable prostate cancer: a systematic review and meta-analysis, Eur Urol, 82, 82, 10.1016/j.eururo.2022.03.031

Attard, 2022, Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol, Lancet, 399, 447, 10.1016/S0140-6736(21)02437-5

Mottet, 2012, Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial, Eur Urol, 62, 213, 10.1016/j.eururo.2012.03.053

Ventimiglia, 2019, A Systematic review of the role of definitive local treatment in patients with clinically lymph node-positive prostate cancer, Eur Urol Oncol, 2, 294, 10.1016/j.euo.2019.02.001

Seisen, 2018, Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis, Eur Urol, 73, 452, 10.1016/j.eururo.2017.08.011

James, 2015, Survival with newly diagnosed metastatic prostate cancer in the “Docétaxel Era”: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019), Eur Urol, 67, 1028, 10.1016/j.eururo.2014.09.032

James, 2016, Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE Trial, JAMA Oncol, 2, 348, 10.1001/jamaoncol.2015.4350

Sarkar, 2019, Association between radical prostatectomy and survival in men with clinically node-positive prostate cancer, Eur Urol Oncol, 2, 584, 10.1016/j.euo.2018.09.015

James, 2017, Abiraterone for prostate cancer not previously treated with hormone therapy, N Engl J Med, 377, 338, 10.1056/NEJMoa1702900

Blana, 2009, High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure, BJU Int, 104, 1058, 10.1111/j.1464-410X.2009.08518.x

Van den Broeck, 2019, Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review, Eur Urol, 75, 967, 10.1016/j.eururo.2018.10.011

Panebianco, 2021, Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): international consensus-based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy, Eur Urol Oncol, 4, 868, 10.1016/j.euo.2021.01.003

Renard-Penna, 2015, [Imagery of treated prostate cancer], Prog Urol, 25, 128, 10.1016/j.purol.2014.12.002

Zapatero, 2011, Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease?, Int J Radiat Oncol Biol Phys, 81, 1279, 10.1016/j.ijrobp.2010.07.1975

Marzola, 2013, Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution, Clin Nucl Med, 38, e26, 10.1097/RLU.0b013e318266cc38

Mapelli, 2016, 11C- or 18F-choline PET/CT for imaging evaluation of biochemical recurrence of prostate cancer, J Nucl Med, 57, 43S, 10.2967/jnumed.115.169755

Gauthe, 2019, Impact of sodium (18)F-fluoride PET/CT, (18)F-fluorocholine PET/CT and whole-body diffusion-weighted MRI on the management of patients with prostate cancer suspicious for metastasis: a prospective multicentre study, World J Urol, 37, 1587, 10.1007/s00345-018-2547-5

Evangelista, 2013, Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis, Clin Nucl Med, 38, 305, 10.1097/RLU.0b013e3182867f3c

Perera, 2020, Eur Urol, 77, 403, 10.1016/j.eururo.2019.01.049

Fourquet, 2021, Restaging the biochemical recurrence of prostate cancer with [(68)Ga]Ga-PSMA-11 PET/CT: diagnostic performance and impact on patient disease management, Cancers (Basel), 13, 1594, 10.3390/cancers13071594

Rousseau, 2019, A prospective study on (18)F-DCFPyL PSMA PET/CT imaging in biochemical recurrence of prostate cancer, J Nucl Med, 60, 1587, 10.2967/jnumed.119.226381

Scarsbrook, 2020, Effect of (18)F-Fluciclovine positron emission tomography on the management of patients with recurrence of prostate cancer: results from the FALCON Trial, Int J Radiat Oncol Biol Phys, 107, 316, 10.1016/j.ijrobp.2020.01.050

Jani, 2021, (18)F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial, Lancet, 397, 1895, 10.1016/S0140-6736(21)00581-X

Calais, 2019, (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial, Lancet Oncol, 20, 1286, 10.1016/S1470-2045(19)30415-2

Bolla, 2012, Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911), Lancet, 380, 2018, 10.1016/S0140-6736(12)61253-7

Thompson, 2009, Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial, J Urol, 181, 956, 10.1016/j.juro.2008.11.032

Wiegel, 2014, Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial, Eur Urol, 66, 243, 10.1016/j.eururo.2014.03.011

Sargos, 2020, Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial, Lancet Oncol, 21, 1341, 10.1016/S1470-2045(20)30454-X

Parker, 2020, Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial, Lancet, 396, 1413, 10.1016/S0140-6736(20)31553-1

Kneebone, 2020, Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial, Lancet Oncol, 21, 1331, 10.1016/S1470-2045(20)30456-3

Vale, 2020, Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data, Lancet, 396, 1422, 10.1016/S0140-6736(20)31952-8

Stish, 2016, Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer, J Clin Oncol, 34, 3864, 10.1200/JCO.2016.68.3425

Tilki, 2021, Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death, J Clin Oncol, 39, 2284, 10.1200/JCO.20.03714

Jairath, 2021, A systematic review of the evidence for the decipher genomic classifier in prostate cancer, Eur Urol, 79, 374, 10.1016/j.eururo.2020.11.021

Shelley, 2009, A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma, Cancer Treat Rev, 35, 9, 10.1016/j.ctrv.2008.08.002

Messing, 2006, Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy, Lancet Oncol, 7, 472, 10.1016/S1470-2045(06)70700-8

Briganti, 2009, Eur Urol, 55, 261, 10.1016/j.eururo.2008.09.043

Engel, 2010, Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer, Eur Urol, 57, 754, 10.1016/j.eururo.2009.12.034

Marra, 2020, Management of patients with node-positive prostate cancer at radical prostatectomy and pelvic lymph node dissection: a systematic review, Eur Urol Oncol, 3, 565, 10.1016/j.euo.2020.08.005

Abdollah, 2014, Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer, J Clin Oncol, 32, 3939, 10.1200/JCO.2013.54.7893

Ploussard, 2021, Management of persistently elevated prostate-specific antigen after radical prostatectomy: a systematic review of the literature, Eur Urol Oncol, 4, 150, 10.1016/j.euo.2021.01.001

Godoy, 2009, Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy?, Urology, 74, 167, 10.1016/j.urology.2008.07.067

Ploussard, 2014, Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study, World J Urol, 32, 1331, 10.1007/s00345-013-1214-0

Gauthe, 2022, Restaging of patients with persistently elevated prostate-specific antigen after radical prostatectomy using [(68)Ga]-PSMA-11 positron emission tomography/computed tomography: impact on disease management, Eur Urol, 81, e87, 10.1016/j.eururo.2022.01.012

Pfister, 2014, Early salvage radiotherapy following radical prostatectomy, Eur Urol, 65, 1034, 10.1016/j.eururo.2013.08.013

Yokomizo, 2020, Salvage radiotherapy versus hormone therapy for prostate-specific antigen failure after radical prostatectomy: a randomised, multicentre, open-label, phase 3 trial (JCOG0401)(dagger), Eur Urol, 77, 689, 10.1016/j.eururo.2019.11.023

Ghadjar, 2021, Dose-intensified versus conventional-dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: the SAKK 09/10 randomized phase 3 trial, Eur Urol, 80, 306, 10.1016/j.eururo.2021.05.033

Qi, 2020, Toxicity and biochemical outcomes of dose-intensified postoperative radiation therapy for prostate cancer: results of a randomized phase III trial, Int J Radiat Oncol Biol Phys, 106, 282, 10.1016/j.ijrobp.2019.09.047

Pollack, 2022, The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial, Lancet, 399, 1886, 10.1016/S0140-6736(21)01790-6

Roach, 2018, The impact of (68)Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study, J Nucl Med, 59, 82, 10.2967/jnumed.117.197160

le Guevelou, 2021, PET/CT-based salvage radiotherapy for recurrent prostate cancer after radical prostatectomy: impact on treatment management and future directions, Front Oncol, 11, 742093, 10.3389/fonc.2021.742093

Carrie, 2016, Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial, Lancet Oncol, 17, 747, 10.1016/S1470-2045(16)00111-X

Carrie, 2019, Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial, Lancet Oncol, 20, 1740, 10.1016/S1470-2045(19)30486-3

Shipley, 2017, Radiation with or without antiandrogen therapy in recurrent prostate cancer, N Engl J Med, 376, 417, 10.1056/NEJMoa1607529

Tendulkar, 2016, Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy, J Clin Oncol, 34, 3648, 10.1200/JCO.2016.67.9647

Trock, 2008, Prostate cancer-specific survival following salvage radiotherapy vs. observation in men with biochemical recurrence after radical prostatectomy, JAMA, 299, 2760, 10.1001/jama.299.23.2760

Chade, 2012, Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature, Eur Urol, 61, 961, 10.1016/j.eururo.2012.01.022

Hennequin, 2017, Management of local relapse after prostate cancer radiotherapy: surgery or radiotherapy?, Cancer Radiother, 21, 433, 10.1016/j.canrad.2017.07.026

Crook, 2022, Salvage low-dose-rate prostate brachytherapy: clinical outcomes of a phase 2 trial for local recurrence after external beam radiation therapy (NRG Oncology/RTOG 0526), Int J Radiat Oncol Biol Phys, 112, 1115, 10.1016/j.ijrobp.2021.10.138

Valle, 2021, A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER), Eur Urol, 80, 280, 10.1016/j.eururo.2020.11.010

Pasquier, 2019, GETUG-AFU 31: a phase I/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy-study protocol, BMJ Open, 9, e026666, 10.1136/bmjopen-2018-026666

Crouzet, 2012, Locally recurrent prostate cancer after initial radiation therapy: early salvage high-intensity focused ultrasound improves oncologic outcomes, Radiother Oncol, 105, 198, 10.1016/j.radonc.2012.09.014

Siddiqui, 2015, Comparative morbidity of ablative energy-based salvage treatments for radio-recurrent prostate cancer, Can Urol Assoc J, 9, 325, 10.5489/cuaj.3113

Mouraviev, 2012, Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy, Eur Urol, 61, 1204, 10.1016/j.eururo.2012.02.051

Williams, 2011, Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer, Eur Urol, 60, 405, 10.1016/j.eururo.2010.12.012

Duchesne, 2016, Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial, Lancet Oncol, 17, 727, 10.1016/S1470-2045(16)00107-8

van den Bergh, 2016, Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: a systematic review, Eur Urol, 69, 802, 10.1016/j.eururo.2015.11.023

Crook, 2012, Intermittent androgen suppression for rising PSA level after radiotherapy, N Engl J Med, 367, 895, 10.1056/NEJMoa1201546

Scheltema, 2017, Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project, World J Urol, 35, 695, 10.1007/s00345-016-1932-1

Ploussard, 2015, Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature, J Urol, 194, 983, 10.1016/j.juro.2015.04.103

Ploussard, 2019, Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review, Eur Urol, 76, 493, 10.1016/j.eururo.2018.10.041

Bravi, 2020, Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought, Eur Urol, 78, 661, 10.1016/j.eururo.2020.06.043

Supiot, 2021, OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate Cancer, Eur Urol, 80, 405, 10.1016/j.eururo.2021.06.010

Lepinoy, 2019, Salvage extended field or involved field nodal irradiation in (18)F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer, Eur J Nucl Med Mol Imaging, 46, 40, 10.1007/s00259-018-4159-0

Suardi, 2015, Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years, Eur Urol, 67, 299, 10.1016/j.eururo.2014.02.011

Fossati, 2019, Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: results from a large, multi-institutional analysis, Eur Urol, 75, 176, 10.1016/j.eururo.2018.09.009

Rischke, 2015, Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only, Strahlenther Onkol, 191, 310, 10.1007/s00066-014-0763-5